Iovance Biotherapeutics Inc. held its Annual Meeting of Stockholders on June 10, 2025, via live webcast. Stockholders voted on several proposals: the election of Iain Dukes, Athena Countouriotis, Ryan Maynard, Wayne Rothbaum, Frederick Vogt, Michael Weiser, and Wendy Yarno to the Board of Directors was approved. The ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved. An amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant by 12,500,000 shares was approved. An amendment to the 2020 Employee Stock Purchase Plan to increase the number of shares available for grant by 1,000,000 shares was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.